AU2001254561A1 - Immunizing against hiv infection - Google Patents

Immunizing against hiv infection

Info

Publication number
AU2001254561A1
AU2001254561A1 AU2001254561A AU5456101A AU2001254561A1 AU 2001254561 A1 AU2001254561 A1 AU 2001254561A1 AU 2001254561 A AU2001254561 A AU 2001254561A AU 5456101 A AU5456101 A AU 5456101A AU 2001254561 A1 AU2001254561 A1 AU 2001254561A1
Authority
AU
Australia
Prior art keywords
hiv infection
against hiv
immunizing against
immunizing
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254561A
Inventor
Shi-Xian Cao
Michel H Klein
Roy Persson
Benjamin Rovinski
James Tartaglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
AVENTIS PASTEUR
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVENTIS PASTEUR, Aventis Pasteur Ltd filed Critical AVENTIS PASTEUR
Publication of AU2001254561A1 publication Critical patent/AU2001254561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001254561A 2000-04-27 2001-04-25 Immunizing against hiv infection Abandoned AU2001254561A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20001100P 2000-04-27 2000-04-27
US60200011 2000-04-27
PCT/CA2001/000577 WO2001082962A2 (en) 2000-04-27 2001-04-25 Immunizing against hiv infection

Publications (1)

Publication Number Publication Date
AU2001254561A1 true AU2001254561A1 (en) 2001-11-12

Family

ID=22739938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254561A Abandoned AU2001254561A1 (en) 2000-04-27 2001-04-25 Immunizing against hiv infection

Country Status (8)

Country Link
US (4) US20040013684A1 (en)
EP (1) EP1280551B1 (en)
AU (1) AU2001254561A1 (en)
CA (1) CA2416725A1 (en)
DE (1) DE60125927T2 (en)
DK (1) DK1280551T3 (en)
ES (1) ES2282251T3 (en)
WO (1) WO2001082962A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
EP2388015A1 (en) 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
EP1278541A1 (en) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
AU2002252199B2 (en) 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
PL1605971T3 (en) * 2003-03-26 2010-10-29 Wyeth Llc Immunogenic composition and methods
US20060257416A1 (en) * 2003-06-13 2006-11-16 Palmowski J M Materials and methods for improved vaccination
WO2011106100A2 (en) 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
CN1111540C (en) * 1993-06-09 2003-06-18 康诺特实验室有限公司 Placed in-line synthetic HIV-1 peptide class
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate

Also Published As

Publication number Publication date
DE60125927T2 (en) 2007-10-18
US20050287174A1 (en) 2005-12-29
DK1280551T3 (en) 2007-05-21
EP1280551B1 (en) 2007-01-10
CA2416725A1 (en) 2001-11-08
US20040013684A1 (en) 2004-01-22
WO2001082962A2 (en) 2001-11-08
WO2001082962A3 (en) 2002-03-21
ES2282251T3 (en) 2007-10-16
EP1280551A2 (en) 2003-02-05
DE60125927D1 (en) 2007-02-22
US20020051770A1 (en) 2002-05-02
US20090142373A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
AU2002236159A1 (en) Immunogenic complex
AU2002224520A1 (en) A cannula
AU2001227916A1 (en) Earplug
AU2002223827A1 (en) Well treatment
AU2001274548A1 (en) Syringe
AU2002254558A1 (en) Novel vaccine
AU2001280598A1 (en) Anti-occlusion catheter
AU1285300A (en) Hiv vaccine
AU2002217748A1 (en) Shrouded bomb
AU1408300A (en) Hiv infection inhibitors
AU6594401A (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
AU2001289831A1 (en) Medicaments against viral infections
AU2001240791A1 (en) Sequence
AU2002212914A1 (en) Autofocusing
AU2001254561A1 (en) Immunizing against hiv infection
AUPQ948800A0 (en) A vaccine strategy
AU6158700A (en) Vaccine
AUPR030800A0 (en) Immunomodulatory preparation
AU6904101A (en) Infection model
AU2002239395A1 (en) Hiv treatment with benzimidazoles
AU2001267541A1 (en) Vaccine composition
AU5811600A (en) Vaccine
AU5274099A (en) Hiv vaccine
AU2002211324A1 (en) Oxidoreductases
AU2000279374A1 (en) Secure syringe